Literature DB >> 27190271

Deciphering signaling networks in osteosarcoma pathobiology.

Christos Adamopoulos1, Antonios N Gargalionis1, Efthimia K Basdra1, Athanasios G Papavassiliou2.   

Abstract

Osteosarcoma is the most frequent type of primary bone tumors among children and adolescents. During the past years, little progress has been made regarding prognosis of osteosarcoma patients, especially for those with metastatic disease. Genomic instability and gene alterations are common, but current data do not reveal a consistent and repeatable pattern of osteosarcoma development, thus paralleling the tumor's high heterogeneity. Critical signal transduction pathways have been implicated in osteosarcoma pathobiology and are being evaluated as therapeutic targets, including receptor activator for nuclear factor-κB (RANK), Wnt, Notch, phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin, and mechanotransduction pathways. Herein, we recapitulate and discuss recent advances in the context of molecular mechanisms and signaling networks that contribute to osteosarcoma progression and metastasis, towards patient-tailored and novel-targeted treatments.
© 2016 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Osteosarcoma; activator protein-1; mammalian target of rapamycin; mechanotransduction; nuclear factor-κB; signal transduction

Mesh:

Year:  2016        PMID: 27190271      PMCID: PMC4950271          DOI: 10.1177/1535370216648806

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  90 in total

1.  Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.

Authors:  M Enomoto; S Hayakawa; S Itsukushima; D Y Ren; M Matsuo; K Tamada; C Oneyama; M Okada; T Takumi; M Nishita; Y Minami
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

2.  Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.

Authors:  Tetsuro Ohba; Heather A Cole; Justin M M Cates; David A Slosky; Hirotaka Haro; Takashi Ando; Herbert S Schwartz; Jonathan G Schoenecker
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

3.  Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.

Authors:  Irene Sulzbacher; Peter Birner; Martin Dominkus; Bettina Pichlhofer; Peter R Mazal
Journal:  Pathology       Date:  2010-12       Impact factor: 5.306

4.  Rapamycin inhibits tumor growth of human osteosarcomas.

Authors:  Shichang Zhao; Nanji Lu; Yimin Chai; Xingang Yu
Journal:  J BUON       Date:  2015 Mar-Apr       Impact factor: 2.533

5.  Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling.

Authors:  Sara R Martins-Neves; Daniela I Paiva-Oliveira; Pauline M Wijers-Koster; Antero J Abrunhosa; Carlos Fontes-Ribeiro; Judith V M G Bovée; Anne-Marie Cleton-Jansen; Célia M F Gomes
Journal:  Cancer Lett       Date:  2015-11-11       Impact factor: 8.679

Review 6.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

Review 7.  Wnt pathway in osteosarcoma, from oncogenic to therapeutic.

Authors:  Yu Cai; Tiange Cai; Yan Chen
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

8.  Prognostic significance of bone morphogenetic activity in osteosarcoma tissue.

Authors:  H Yoshikawa; K Takaoka; K Masuhara; K Ono; Y Sakamoto
Journal:  Cancer       Date:  1988-02-01       Impact factor: 6.860

9.  Orientation-specific responses to sustained uniaxial stretching in focal adhesion growth and turnover.

Authors:  Yun Chen; Ana M Pasapera; Alan P Koretsky; Clare M Waterman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

Review 10.  Immunotherapy for Bone and Soft Tissue Sarcomas.

Authors:  Takenori Uehara; Tomohiro Fujiwara; Ken Takeda; Toshiyuki Kunisada; Toshifumi Ozaki; Heiichiro Udono
Journal:  Biomed Res Int       Date:  2015-06-17       Impact factor: 3.411

View more
  16 in total

1.  LncRNA SNHG4 promotes tumour growth by sponging miR-224-3p and predicts poor survival and recurrence in human osteosarcoma.

Authors:  Ruida Xu; Fan Feng; Xiaosheng Yu; Zude Liu; Lifeng Lao
Journal:  Cell Prolif       Date:  2018-08-28       Impact factor: 6.831

Review 2.  Molecular genetics of osteosarcoma.

Authors:  Kirby Rickel; Fang Fang; Jianning Tao
Journal:  Bone       Date:  2016-10-17       Impact factor: 4.398

3.  SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.

Authors:  S-J Zhao; Y-Q Jiang; N-W Xu; Q Li; Q Zhang; S-Y Wang; J Li; Y-H Wang; Y-L Zhang; S-H Jiang; Y-J Wang; Y-J Huang; X-X Zhang; G-A Tian; C-C Zhang; Y-Y Lv; M Dai; F Liu; R Zhang; D Zhou; Z-G Zhang
Journal:  Oncogene       Date:  2017-10-30       Impact factor: 9.867

4.  miRNA-133b targets FGFR1 and presents multiple tumor suppressor activities in osteosarcoma.

Authors:  Gan Gao; Zhen Tian; Huan-Ye Zhu; Xun-Yan Ouyang
Journal:  Cancer Cell Int       Date:  2018-12-18       Impact factor: 5.722

5.  Elevated expression of microRNA-328-3p suppresses aggressive malignant behaviors via targeting matrix metalloprotease 16 in osteosarcoma.

Authors:  Ming Zhang; Jiayuan Zhang; Quan Zhou
Journal:  Onco Targets Ther       Date:  2019-03-18       Impact factor: 4.147

6.  Monocyte Chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma.

Authors:  Ju-Fang Liu; Po-Chun Chen; Tsung-Ming Chang; Chun-Han Hou
Journal:  J Exp Clin Cancer Res       Date:  2020-11-23

7.  Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib.

Authors:  Zhehao Dai; Haoyu Tang; Yue Pan; Junquan Chen; Yongping Li; Jun Zhu
Journal:  FEBS Open Bio       Date:  2018-04-24       Impact factor: 2.693

8.  miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.

Authors:  Rui-Da Xu; Fan Feng; Xiao-Sheng Yu; Zu-De Liu; Li-Feng Lao
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

9.  Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways.

Authors:  Hao Lin; Tingrui Wu; Lijiao Peng; Wenmei Su; Yingxin Wang; Xiao Li; Qianzheng Liu; Chanli Zhong; Jing Huang; Bo Wei
Journal:  Int J Med Sci       Date:  2020-08-21       Impact factor: 3.738

10.  Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1.

Authors:  Shenglong Li; Fei Liu; Yi Pei; Wei Wang; Ke Zheng; Xiaojing Zhang
Journal:  Aging (Albany NY)       Date:  2019-09-16       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.